成纤维细胞生长因子-23在心血管疾病中的作用及研究进展  

Research Advancements of the Role of Fibroblast Growth Factor-23 in Cardiovascular Diseases

作　　者：杨玲[1] 朱滨[1] 杨春 

机构地区：[1]常州市第一人民医院苏州大学附属第三医院,江苏常州213003 [2]华中科技大学同济医学院附属同济医院

出　　处：《中外医学研究》2017年第26期154-156,共3页CHINESE AND FOREIGN MEDICAL RESEARCH

基　　金：常州市卫计委重大科技项目(项目编号:ZD201407;ZD201505;ZD201601);常州市科技局基金资助项目(项目编号:CJ20159022;CJ20160030);江苏省"333工程"科研项目(项目编号:BRA2016122)

摘　　要：成纤维细胞生长因子-23(fibroblast growth factor-23,FGF-23)升高与慢性肾脏病(chronic kidney diseases,CKD)患者合并心血管疾病及其发病率和死亡率有关。越来越多的研究证据显示,在肾功能正常人群中FGF-23异常升高与心血管疾病的发生及临床预后存在相关性。本文通过对FGF-23与左室肥厚、动脉粥样硬化、心力衰竭及高血压等疾病的关系研究进行综述,以探讨FGF-23在心血管疾病中的致病作用及可能治疗机制。Increased level of fibroblast growth factor-23（FGF-23） has great higher mortality and morbidity in the patients with the comorbidity of cardiovascular diseases and chronic kidney diseases.Accumulating evidence shows that abnormally up-regulated FGF-23 levels are positively correlated with the incidence and prognosis of cardiovascular diseases in individuals with normal kidney functions.The role of FGF-23 in left ventricular hypertrophy,atherosclerosis,heart failure and hypertension are reviewed in the present study,so as to evaluate the pathogenesis and potential therapeutic targets of FGF-23 for cardiovascular diseases.

关 键 词：成纤维细胞生长因子-23 左室肥厚 动脉粥样硬化 心力衰竭 高血压 

分 类 号：R54[医药卫生—心血管疾病]